Baidu
map

肿瘤第一线 · 学术知识传播

MedSci主页 / 所有栏目 / 肿瘤第一线 · 学术知识传播

Front Oncol:非小细胞肺癌脑转移的局部与全身治疗作为首次治疗的生存比较

2021-11-20 MedSci原创 MedSci原创

研究表明,对于NSCLC脑转移患者,无论是否存在与脑转移相关的临床症状,在局部治疗前进行全身治疗可能更有利于生存。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1866362, encodeId=b84d186636271, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jun 12 20:19:32 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060052, encodeId=4ccd206005210, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Apr 20 14:19:32 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406122, encodeId=a2d71406122fd, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Nov 23 06:19:32 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
    2022-06-12 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1866362, encodeId=b84d186636271, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jun 12 20:19:32 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060052, encodeId=4ccd206005210, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Apr 20 14:19:32 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406122, encodeId=a2d71406122fd, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Nov 23 06:19:32 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1866362, encodeId=b84d186636271, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jun 12 20:19:32 CST 2022, time=2022-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060052, encodeId=4ccd206005210, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Apr 20 14:19:32 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406122, encodeId=a2d71406122fd, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Tue Nov 23 06:19:32 CST 2021, time=2021-11-23, status=1, ipAttribution=)]
    2021-11-23 chg122

相关资讯

一文读懂肿瘤病理分期:早/中/晚期或I/II/III/IV期

肿瘤的治疗讲究的是在循证医学原则指导下的个体化、规范化治疗。而规范化治疗首先要求对病人的病情进行定性和定量评估,然后根据个体化的评估制定不同的治疗方案。

深度解析肺癌早期筛查

癌症的早期筛查和预防,是人类抗癌的重要手段,其重要意义不亚于癌症诊断和治疗上的进步。

延长吉非替尼或厄洛替尼给药间隔时间治疗肺腺癌12例

吉非替尼和厄洛替尼均为EGFR酪氨酸激酶抑制剂(TKI),在EGFR突变的非小细胞肺癌的治疗中显示出良好效果,即使是化疗过的患者,OS可达22.8个月和24.5个月研究证实高于吉非替尼的标准剂量给药并

非小细胞肺癌EGFR基因突变检测技术进展

非小细胞肺癌是临床上十分常见的恶性肿瘤疾病, 据相关报告统计, 在我国非小细胞肺癌占肺癌总数的80%以上, 严重影响了我国广大人民群众的身体健康与生命安全

一文读懂肺癌病理报告

病理诊断是鉴别是否患上癌症的金标准。

不同亚型早期鼻咽NK/T细胞淋巴瘤75例临床分析

评估早期鼻咽NK/T细胞淋巴瘤(NKTCL)不同亚型的临床特征和生存预后差异

Baidu
map
Baidu
map
Baidu
map